You are here: Home Our Members Principal Investigators
Silke Lassmann Profile Page
Silke Lassmann


Lab: Prof. Dr. Silke Lassmann
Department: Institute of Surgical Pathology
University Medical Center Freiburg
Address: Breisacherstr. 115 a
79106 Freiburg
Phone: +49 761 270 80620
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Lab homepage:
PhD positions available: YES
Research Area: Molecular Medicine
Research Interests: Our research group is interested in “molecular tumorpathology”, focussing on the biology of solid tumours by translational approaches. Our aim is to decipher basic molecular mechanisms of tumour development and progression, in particular with respect to (epi-)genetic instability and signalling pathways. We envisage using this basic molecular knowledge to evaluate novel applications of molecular pathology in a clinically-relevant setting, specifically addressing the issue of therapy prediction. In this context, we continuously work on new development or the “fine-tuning” of “state of the art” techniques for application to human tissue specimens. Close collaboration with other pathology- and clinic-based research groups as well as with researcher groups in the field of material and natural sciences and biostatistics greatly support our research goals.


Education & Training: 2013-2015: Study of Economics & Management, TU Kaiserslautern, Germany (MA)
2012-2013: Study of Health Care Management, University of Freiburg, Germany (Certificate of Advanced Studies)
1994-1998: PhD work and degree at University of London, Great Britain (PhD Biochemistry)
1991-1994: Study of Physiology, King’s College, University of London, Great Britain (BSc)
Employment & Experience: since 2016: Supervisor diagnostic molecular pathology, Institute of Surgical Pathology, Medical Center – University of Freiburg
since 2007: Permanent position, Medical Center - University of Freiburg, Germany
since 2002: Senior Research Associate / Group Leader, Institute of Surgical Pathology, Medical Center – University of Freiburg (Prof. Dr. med. M. Werner), Germany
2000-2001: Research Associate (Group: Prof. Dr. M. Werner), Institute of Pathology, Klinikum r.d. Isar, Technische Universität München, Munich, Germany
1998-1999: Research Associate / “PostDoc” (Group: Prof. Dr. IL Campbell), The Scripps Research Institute, La Jolla, California, USA
1994-1997: Research Associate / PhD.-student (Dept. Prof. Dr. H. Wekerle), Max-Planck Institut für Neurobiologie, Martinsried, Germany - and – „External Student MPhil./PhD.“, University of London, Great Britain
Scientific Activities: since 2015: Co-leader Comprehensive Cancer Center Freiburg Molecular Tumorboard
since 2013: Principal investigator, German Cancer Consortium (DKTK)
since 2012: Principal investigator, Collaborative Research Center SFB992 “Medical Epigenetics”, DFG
since 2011: Associate member of the BIOSS Center for Biological Signalling Studies
since 2010: Principal investigator, Collaborative Research Center SFB850 “Control of Cell Motility in Morphogenesis, Cancer Invasion and Migration”, DFG


Honors and Awards:

2015: Award of “Master of Arts”, TU Kaiserslautern, Germany
2012: Award „Außerplanmäßige Professorin“, University of Freiburg, Germany
2008: Award “Habilitation“/„Venia legendi“ (Molecular Pathology), University of Freiburg, Germany
2007: Award „Best Research Contribution “, Deut. Gesell. für Pathologie, Germany
1998-1999: Stipend, Deutscher Akademischer Austauschdienst, Germany
1991-1997: Travel Stipend, British Society of Immunology, Great Britain
1998: Doctor of Philosophy, University of London, Great Britain (PhD., Biochemistry)
1996: Invitation/Participation 46th Meeting of Nobel Laureates, Lindau, Germany
1994: Bachelor of Science, King’s College, University of London, Great Britain (BSc.)
1994: Stipend, City of Westminster, London, Great Britain


Selected Publications:

Geißler AL, Geißler M, Kottmann D, Lutz L, Fichter CD, Fritsch R, Weddeling B, Makowiec F, Werner M, Lassmann S. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. Oncotarget. 2017 Feb 9.  Abstract

Kovaleva V, Geissler AL, Lutz L, Fritsch R, Makowiec F, Wiesemann S, Hopt UT, Passlick B, Werner M, Lassmann S. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Mol Cancer. 2016 Oct 18;15(1):63.  Abstract

Lutz L, Fitzner IC, Ahrens T, Geißler AL, Makowiec F, Hopt UT, Bogatyreva L, Hauschke D, Werner M, Lassmann S. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro. Am J Cancer Res. 2016 Feb 15;6(3):664-76.  Abstract

Ahrens TD, Timme S, Ostendorp J, Bogatyreva L, Hoeppner J, Hopt UT, Hauschke D, Werner M, Lassmann S. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity. Lab Invest. 2016 Mar;96(3):307-16.  Abstract

Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics. 2015;10(5):431-45. Abstract

Herr R, Köhler M, Andrlová H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 2015 Jan 1;75(1):216-29.  Abstract

Fichter CD, Gudernatsch V, Przypadlo CM, Follo M, Schmidt G, Werner M, Lassmann S. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.  J Mol Med (Berl). 2014 Nov;92(11):1209-23. Abstract

Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit VI, Follo M, Hasenburg A,  Köhler M, Dierbach H, Herzog S, Proske A, Werner M, Dengjel J, Brummer T, Laßmann S, Wäsch R, Zeiser R. Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer. Int J Cancer. 2015 May 15;136(10):2328-40. Abstract

Fichter CD, Timme S, Braun JA, Gudernatsch V, Schöpflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M, Lassmann S. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer. 2014 Oct 1;135(7):1517-30.  Abstract

Timme S, Ihde S, Fichter CD, Waehle V, Bogatyreva L, Atanasov K, Kohler I, Schöpflin A, Geddert H, Faller G, Klimstra D, Tang L, Reinheckel T, Hauschke D, Busch H, Boerries M, Werner M, Lassmann S. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. Oncogene. 2014 Jun 19;33(25):3256-66.  Abstract

Copyright © 2009-2020 University of Freiburg